Clinical trial • Phase I • Oncology
IOA-244 for Advanced solid tumours | Metastatic cancer
Phase I trial of IOA-244 for Advanced solid tumours | Metastatic cancer. None/Not specified-controlled.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Advanced solid tumours | Metastatic cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 07-10-2024
- First CTIS Authorization Date
- 16-12-2024
Trial design
None/Not specified-controlled Phase I trial across 1 site in Italy.
- Comparator
- None/Not specified
- Single Multiple Or Escalation Dose Combined
- Yes
Recruitment
- Recruitment Window Months
- 89
Geography
- Total Number Of Sites
- 1
Italy
- Earliest CTIS Part Ii Submission Date
- 17-10-2024
- Latest Decision Or Authorization Date
- 13-02-2026
- Processing Time Days
- 484
- Number Of Sites
- 1
- Number Of Participants
- 34
Sites
- Site Name
- Azienda Ospedaliera Universitaria Senese
- Department Name
- U.O.C. Immunoterapia Oncologica
- Principal Investigator Name
- Michele Maio
- Principal Investigator Email
- maio@ao-siena.toscana.it
- Contact Person Name
- Michele Maio
- Contact Person Email
- maio@ao-siena.toscana.it
Sponsor
Primary sponsor
- Full Name
- iOnctura SA
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Switzerland
Investigational products
- Investigational Product Name
- IOA-244
- First In Human
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)